1061337-51-6

Basic information

• Product Name: Lefamulin
• Synonyms: Lefamulin;2-[[(1R,2R,4R)-4-Amino-2-hydroxycyclohexyl]thio]acetic acid (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester;BC 3781;Lefamulin(BC-3781)
• CAS NO: 1061337-51-6
• Molecular Formula: C₂₈H₄₅NO₅S
• Molecular Weight: 507.7256
• Product Categories: API
• Mol File: 1061337-51-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 618.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• PKA: 14.45±0.60(Predicted)
• CAS DataBase Reference: Lefamulin(CAS DataBase Reference)
• NIST Chemistry Reference: Lefamulin(1061337-51-6)
• EPA Substance Registry System: Lefamulin(1061337-51-6)

Safety Data

• Hazardous Substances Data: 1061337-51-6(Hazardous Substances Data)

Usage

Description

Lefamulin is a semi-synthetic pleuromutilin antibiotic that works by inhibiting bacterial protein synthesis, making it effective against a range of bacterial infections.

Uses

Used in Pharmaceutical Industry:
Lefamulin is used as an antibiotic medication for the treatment of adults with community-acquired bacterial pneumonia. It is effective against various bacterial strains, including Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae, providing a valuable treatment option for patients with pneumonia.

Upstream product

• 1352834-06-0 cyclohex-3-ene-1-carboxylic acid (S)-1-phenylethanamine salt 
• 1350636-75-7 [(1R,3R,4R)-3-hydroxy-4-mercaptocyclohexyl]carbamic acid tert-butyl ester 
• 1352834-02-6 C₇H₉NO 
• 1350636-79-1 14-O-{(1R,2R,4R)-[(2,2,2-trifluoroacetyl)-amino-2-hydroxy-cyclohexyl-sulfanyl]-acetyl}-mutilin 
• 1350636-78-0 2,2,2-trifluoro-N-[(1R,3R,4R)-3-hydroxy-4-mercapto-cyclohexyl]-acetamide 
• 1350636-92-8 {(1R,2R,4R)-4-[(2,2,2-trifluoro-acetyl)-amino]-2-hydroxy-cyclohexyl} benzene-carbothioate 
• 1350636-89-3 {(1R,2R,4R)-4-[(tert-butoxycarbonyl)amino]-2-hydroxycyclohexyl}phenyl thioformate 
• 1350636-87-1 (R)-(3-cyclohexenyl)carbamic acid tert-butyl ester 
• 1350636-88-2 (1R,3R,6S)-(7-oxabicyclo[4.1.0]hept-3-yl)carbamic acid tert-butyl ester 
• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 31716-01-5 pleuromutilin tosylate 
• 5709-98-8 (R)-cyclohex-3-enecarboxylic acid 
• 1061660-17-0 14-O-{[(1RS,2RS,4RS)-4-tert-butoxycarbonylamino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin 

Downstream Products

• 1350636-86-0 14-O-{[(1R,2R,4R)-2-hydroxy-4-(phthalimido-N-yl)-cyclohexyl-sulfanyl]-acetyl}-mutilin 
• 1350636-84-8 14-O-{[(1R,2R,4R)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin hydrogenmaleate 
• 1350636-79-1 14-O-{(1R,2R,4R)-[(2,2,2-trifluoroacetyl)-amino-2-hydroxy-cyclohexyl-sulfanyl]-acetyl}-mutilin 
• 1350636-83-7 14-O-{[(1R,2R,4R)-4-amino-2-hydroxy-cyclohexylsulfanyl]-acetyl}-mutilin L-lactate 
• 1350636-82-6 lefamulin acetate 

Relevant articles and documents

Pleuromutilin compounds for treating novel coronavirus pneumonia secondary bacterial infectious diseases

The present invention relates to novel pleuromutilin compounds, and a pharmaceutical composition and a use method thereof. Furthermore, the present invention also relates to a therapeutic method for treating bacterial infections, including infections caused by resistant microorganisms including multiple resistant microorganisms. The method and the compounds for treating secondary bacterial infectious diseases of novel coronavirus (COVID-19 or SARS-Cov-2) pneumonia, and the pharmaceutical composition of the compounds are especially provided, and provide scientific and technological support forwin-win new coronapneumonia epidemic prevention and control obstructing warfare.

PROCESS FOR THE PREPARATION OF PLEUROMUTILINS

Process for the preparation of a Compound of formula I in the form of a single stereoisomer in crystalline form, comprising deprotecting the amine group in a Compound of formula IIa or in a mixture of a compound of formula IIa With a compound of formula IIb and isolating a Compound of formula I from the reaction mixture; Compounds and salts of Compounds of formula I in crystalline form; pharmaceutical compositions comprising such salts; processes for the preparation of intermediates and intermediates in a process for the preparation of a Compound of formula I.